The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).
E. Angevin
No relevant relationships to disclose
V. Grünwald
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Pfizer
A. Ravaud
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
D. E. Castellano
No relevant relationships to disclose
C. C. Lin
No relevant relationships to disclose
J. E. Gschwend
Consultant or Advisory Role - Novartis
Honoraria - Novartis
A. L. Harzstark
No relevant relationships to disclose
J. Chang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Y. Wang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
M. M. Shi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
B. J. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche